Nguyen Bao Ngoc, Do Thi Ly, Esther Derouet, Nguyen Huu Tuan Dung, Nguyen Thanh Tung, Nguyen Thi Phuong Linh, Nguyen Hoang Nam, Nguyen Minh Hieu, Nguyen Dinh Thang, Nguyen Thi Van Anh, Pham Thi Thu Huong

Main Article Content

Abstract

Abstract: This research aims to develop and characterize a protein drug delivery system in agarose-glucan complex. The complex was produced by sonicating the mixture of agarose-glucan components and a protein in liquid paraffin with Sonics Vibracell Processor adapted from the method of Nuo Wang et all 1997. Etanercept, an anti-tumor necrosis factor-alpha (anti-TNF-α), was used as a model protein drug which was successfully encapsulated into agarose-glucan complex system. This protein can neutralize the TNF-α, a pro-inflammatory cytokine that plays a pivotal role in regulating the inflammatory response in rheumatoid arthritis (RA) and is well-known as mediator worsening RA pathogenesis. The prepared agarose-glucan complex possesses a range of sizes, from 30 to 150 nm, dissolves well within the range of pH buffer from 5.2 to 6.2 with an average protein encapsulating efficiency up to 74.4%, and can release up to 50% of protein after 40.3 hours. This research is the basis for developing nanogel-sized targeted drug delivery in RA treatment.


Keywords: Agarose gel, agarose microspheres, glucan, emulsification cooling, rheumatoid arthritis.


References
[1] N. Wang and X.S. Wu, Preparation and Characterization of Agarose Hydrogel Nanoparticles for Protein and Peptide Drug Delivery. Pharmaceutical Development and Technology 2(2) (1997) 135-142.
[2] Zhi-gang Jing, Chun-yu YANG, Chun-li YANG, Hailing Liu, Shuo Yang: Preparation of Homogeneous and Controllable Agarose Micro-beads. Advances in Sciences and Engineering (2016).
[3] Nuo Wang, Xue Shen Wu, A novel approach to stabilization of protein drugs in poly(lactic-co-glycolic acid) microspheres using agarose hydrogel. International Journal of Pharmaceutics 166(1) (1998) 1-14.
[4] P.R. Taylor, S.V. Tsoni, J.A. Willment, K.M. Dennehy, M. Rosas, H. Findon, K. Haynes, C. Steele, M. Botto, S. Gordon, Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nature immunology 8(1) (2007) 31-38.
[5] M. Kanke, E. Tanabe, H. Katayama, Y. Koda, H. Yoshitomi, Application of curdlan to controlled drug delivery. III. Drug release from sustained release suppositories in vitro. Biological and Pharmaceutical Bulletin 18(8) (1995), 1154-1158.
[6] Beom Soo Kim, In Duck Jung, Jong Sik Kim, Jung-heon Lee, In Young Lee, Kyung Bok Lee, . Biotechnology letters 22(14) (2000), 1127-1130.
[7] E.H. Choy and G.S. Panayi, Cytokine pathways and joint inflammation in rheumatoid arthritis, New England Journal of Medicine 344(12) (2001) 907-916.
[8] C.Tetta, G. Camussi, V. Modena, C. Di Vittorio, C. Baglioni, Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Annals of the Rheumatic Diseases, 49(9) (1990) 665-667.
[9] J. F. Fries, Current treatment paradigms in rheumatoid arthritis, Rheumatology 39, (2000) 30–35.
[10] I. H. Tarner, U. Müller-Ladner. Drug delivery systems for the treatment of rheumatoid arthritis. Expert opinion on drug delivery 5(9) (2008) 1027-1037.
[11] Chen Y.F., P. Jobanputra, P. Barton, S. Jowett, S. Bryan, W. Clark, A. Fry-Smith, A. Burls, A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10(42) iii-iv, xi-xiii (2006), 1-229.
[12] P.S. Zehra Kaymakcalan, Sahana Bose, Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble andmembrane tumor necrosis factor, Clinical Immunology 2009.
[13] Y. Tanaka, Current concepts in the management of rheumatoid arthritis. Korean J Intern Med 31(2) (2016) 210-8.
[14] Eun Ju Lee, Joong Kon Park, Saeed A. Khan, Kwang-Hee Lim, Preparation of Agar Nanoparticles by W/O Emulsification.Journal of Chemical Engineering of Japan, 44(7) (2011) 502–508.
[15] Jaleh Varshosaz, Mohammad Reza Zaki, Mohsen Minaiyan, Jaafar Banoozadeh, Preparation, Optimization, and Screening of the Effect of Processing Variables on Agar Nanospheres Loaded with Bupropion HCl by a D-Optimal Design, BioMed Research International 2015, vol. 2015, Article ID 571816, 13 pages, 2015. https://doi.org/10.1155/2015/571816.